The Concise Guide to PHARMACOLOGY 2015/16: Overview
暂无分享,去创建一个
Stephen PH Alexander | John A Peters | Elena Faccenda | Adam J Pawson | Joanna L Sharman | William A Catterall | Helen E Benson | Stephen P. H. Alexander | Anthony J Harmar | John C McGrath | W. Catterall | M. Spedding | E. Faccenda | J. Sharman | H. E. Benson | J. A. Peters | A. Harmar | J. McGrath | Michael Spedding
[1] J. Storch,et al. Tissue-specific Functions in the Fatty Acid-binding Protein Family* , 2010, The Journal of Biological Chemistry.
[2] C. Poüs,et al. The ins and outs of tubulin acetylation: more than just a post-translational modification? , 2011, Cellular signalling.
[3] M. Rasenick,et al. Tubulin, actin and heterotrimeric G proteins: coordination of signaling and structure. , 2014, Biochimica et biophysica acta.
[4] 宁北芳,et al. 疟原虫var基因转换速率变化导致抗原变异[英]/Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .
[5] P. Scherer,et al. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. , 2009, Trends in pharmacological sciences.
[6] Yitao Wang,et al. Adiponectin, an unlocking adipocytokine. , 2009, Cardiovascular therapeutics.
[7] 닐스 론버그,et al. Human ctla-4 antibodies and their uses , 2000 .
[8] A. Beck‐Sickinger,et al. Molecular tools to characterize adiponectin activity. , 2012, Vitamins and hormones.
[9] M. Record,et al. Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands. , 2011, Chemistry and physics of lipids.
[10] B. Dubrovsky. Neurosteroids, neuroactive steroids, and symptoms of affective disorders , 2006, Pharmacology Biochemistry and Behavior.
[11] M. Fasshauer,et al. Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease? , 2012, Diabetologia.
[12] A. Chmurzyńska. The multigene family of fatty acid-binding proteins (FABPs): Function, structure and polymorphism , 2010, Journal of Applied Genetics.
[13] Xinliang Ma,et al. Protective vascular and myocardial effects of adiponectin , 2009, Nature Clinical Practice Cardiovascular Medicine.
[14] 그람헤르만,et al. Antibodies to human IL-1β , 2001 .
[15] C. Mantzoros,et al. The role of adiponectin in cancer: a review of current evidence. , 2012, Endocrine reviews.
[16] X. Codony,et al. Sigma receptors: biology and therapeutic potential , 2004, Psychopharmacology.
[17] T. Matsuo,et al. Classification of FABP isoforms and tissues based on quantitative evaluation of transcript levels of these isoforms in various rat tissues , 2009, Biotechnology Letters.
[18] Megan Lerner,et al. σ Receptors: potential medications development target for anti-cocaine agents , 2003 .
[19] ザルフェルト,ヨッヘン,ゲー.,et al. Human antibodies that bind to human TNFα , 1997 .
[20] C. Buechler,et al. Adiponectin receptor binding proteins – recent advances in elucidating adiponectin signalling pathways , 2010, FEBS letters.
[21] H. R. Payne,et al. Role of Fatty Acid Binding Proteins and Long Chain Fatty Acids in Modulating Nuclear Receptors and Gene Transcription , 2007, Lipids.
[22] M. Furuhashi,et al. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets , 2008, Nature Reviews Drug Discovery.
[23] Yan Lu,et al. An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site , 2012, Pharmaceutical Research.
[24] 陈刚,et al. IL-1β binding antibodies and fragments , 2006 .
[25] Gurneet Kaur,et al. Recent developments in tubulin polymerization inhibitors: An overview. , 2014, European journal of medicinal chemistry.
[26] T. Arumugam,et al. Adiponectin receptor signalling in the brain , 2012, British journal of pharmacology.